Transaction activity across the Healthcare sector remains strong.

Deal volumes are being driven by new technology, new care delivery models, new investors entering the market and the need for more to be achieved from the NHS budget. 

At Catalyst we segment the sector into three key areas – Healthcare Services, Pharmaceuticals (products and services) and Medtech (devices and supplies). Within these we are seeing strong interest and have deal experience in:

  • Contract research organisation services
  • Domiciliary and specialist care
  • Generic pharmaceuticals
  • Primary and Community Care services
  • Telecare devices and services

International partners

Michel  Degryck
Michel Degryck France
Igor  Gorostiaga
Igor Gorostiaga Spain
Hakan Persson
Hakan Persson Sweden
Markus  Decker
Markus Decker Switzerland
Omer  Unsal
Omer Unsal Turkey
Rod Rivera
Rod Rivera USA

Latest deals


Latest thinking

Latest research

research cover Comment & Opinion - Will there be a Brexit boom?

The UK’s decision to leave the EU represents a major opportunity for the country’s dynamic and world-leading pharmaceutical sector – despite warnings that Brexit could prompt pharma companies to quit the UK.

research cover Catalyst Pharma Fast 50

The inaugural Catalyst Pharma Fast 50, our list of the 50 fastest-growing privately owned pharmaceutical companies in the UK in 2016

PDF Catalyst Pharma Fast 50.pdf
Adobe Acrobat file - 3.4 mb
research cover UK Mental Health M&A 2014-2015 snapshot

The emergence of US trade buyers has energised the exit environment for owner managers and investors. We expect further consolidation over the next few years.

PDF UK Mental Health M&A 2014-2015 snapshot.pdf
Adobe Acrobat file - 0.7 mb